SCHEMBL1471136

SCHEMBL1471136

O=C1C=C(c2ccccc2)C(=O)N1c1ccc(I)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 5/20 0.47
FAAH O00519 3/20 0.47
MAPT P10636 4/20 0.45
ALDH1A1 P00352 4/20 0.45
NPSR1 Q6W5P4 3/20 0.45
GAA P10253 2/20 0.45
CCR6 P51684 2/20 0.45
HPGD P15428 2/20 0.45
ALOX12 P18054 2/20 0.45
CACNA1B Q00975 2/20 0.45
APBA1 Q02410 2/20 0.45
LMNA P02545 2/20 0.40
HTT P42858 2/20 0.40
HSP90AA1 P07900 3/20 0.37
RGS4 P49798 1/20 0.37
HCRTR1 O43613 1/20 0.37
S1PR4 O95977 1/20 0.37
S1PR1 P21453 1/20 0.37
ABL1 P00519 1/20 0.36
SRC P12931 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL303331 0.88 ALDH1A1 (0.51) MGLLFAAHMAPTALDH1A1NPSR1
SCHEMBL1471161 0.85 MAPT (0.50) MGLLFAAHMAPTALDH1A1NPSR1
SCHEMBL1473687 0.83 MGLL (0.47) MGLLFAAHMAPTALDH1A1NPSR1
SCHEMBL28976650 0.83 ALDH1A1 (0.45) MGLLFAAHMAPTALDH1A1NPSR1
SCHEMBL1471657 0.83 MAPT (0.54) MGLLFAAHMAPTALDH1A1NPSR1
SCHEMBL1471189 0.83 ALDH1A1 (0.57) MGLLFAAHMAPTALDH1A1NPSR1
SCHEMBL28170453 0.83 NPSR1 (0.47) MGLLFAAHMAPTALDH1A1NPSR1
SCHEMBL1471789 0.83 MGLL (0.54) MGLLFAAHMAPTALDH1A1NPSR1
SCHEMBL4385777 0.82 MGLL (0.49) MGLLFAAHMAPTALDH1A1NPSR1
SCHEMBL8468306 0.81 HSP90AA1 (0.58) MGLLFAAHMAPTALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915304-B2 Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT CONGENIA S.R.L. (IT) 2011-03-29 US disclosed
EP-2091531-B1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S R L (IT) 2010-11-24 EP disclosed
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2010-04-22 US disclosed
EP-2091531-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT Congenia S.r.l. (IT) 2009-08-26 EP disclosed
WO-2008067863-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CYC1, MTPN, TXN2 MGLL 857/4885FAAH 2913/4885MAPT 1947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.